Ginkgo Bioworks Acquires Biotechnology Company Circularis For Undisclosed Terms

RTTNews | Pred 1160 dňami
Ginkgo Bioworks Acquires Biotechnology Company Circularis For Undisclosed Terms

(RTTNews) - Ginkgo Bioworks (DNA), the leading horizontal platform for cell programming, announced Tuesday the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform.

When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality. The Circularis platform also allows ultra-high-throughput screening of promoters and other enhancers.

The Circularis platform strengthens Ginkgo's platform for development of cell and gene therapies, providing the capability to rapidly identify novel promoters with appropriate strength and tissue-specificity designed into customer specific delivery modalities.

read more
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced Thursday the acquisition of microbial innovation firm AgBiome, Inc.'s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
RTTNews | Pred 605 dňami
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.
RTTNews | Pred 697 dňami
Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.
RTTNews | Pred 1231 dňami
Australian Market Extends Early Losses In Mid-market

Australian Market Extends Early Losses In Mid-market

The Australian stock market is extending its early losses in mid-market trading on Monday, but reversing the gains in the previous session, despite the broadly positive cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is staying well below the 8,650.00 level, with weakness across most sectors led by gold miners and energy stocks.
RTTNews | Pred 2 h 27 min